EGb 761 120 mg + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Jun 1, 2008 → Oct 1, 2011
NCT ID
NCT00824512About EGb 761 120 mg + Placebo
EGb 761 120 mg + Placebo is a phase 2 stage product being developed by Ipsen for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT00824512. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00824512 | Phase 2 | Completed |
Competing Products
20 competing products in Friedreich Ataxia